Showing 5971-5980 of 7313 results for "".
- Sciton Unveils mJOULE Platform Featuring BBL HERO And MOXIhttps://practicaldermatology.com/news/sciton-unveils-mjoule-platform-featuring-bbl-hero-and-moxi/2460420/Sciton Inc. is rolling out their mJOULE dual-wavelength platform which includes a new fractional treatment, MOXI, and BBL HERO. MOXI delivers non-ablative laser energy to revitalize skin and BroadBand Light HERO (High Energy Rapid Output) allows practitioners to treat the entire body wi
- Alastin Skincare's INhance Post-Injection Serum Reduces Bruisinghttps://practicaldermatology.com/news/alastin-skincares-inhance-post-injection-serum-reduces-bruising/2460419/Alastin’s Skincare’s INhance Post-Injection Serum with TriHex Technology can help reduce post-injection bruising and swelling, according to a report inthe Journal of Drugs in Dermatology. In
- ProTransit to Target Photodamage in Trials of New Nanoparticle Technologyhttps://practicaldermatology.com/news/protransit-to-target-photodamage-in-trials-of-new-nanoparticle-technology/2460418/ProTransit Nanotherapy plans to launch human clinical trials this summer with products that could target precursors of skin cancers. The company has developed therapies based nanoparticle technology invented at the University of Nebraska Medical Center to help prevent and potentially improve suns
- New from Obagi: Two Sunscreens and a Hydrating Serumhttps://practicaldermatology.com/news/new-from-obagi-two-sunscreens-and-a-hydrating-serum/2460415/Obagi is launching two new Physical Defense Sunscreens and Daily Hydro-Drops. The new SUZANOBAGIMD Physical Defense Sunscreens, available in broad-spectrum SPF 40 and tinted SPF 50, defend against five light sources, including high energy visible light, or blue light, visible light
- Potential Stem Cell Research Breakthrough: Researchers Grow Hairy Skin from Human Stem Cellshttps://practicaldermatology.com/news/potential-stem-cell-research-breakthrough-researchers-grow-hairy-skin-from-human-stem-cells/2460414/Scientists from Indiana University School of Medicine and Harvard Medical School have determined how to grow hairy skin using human stem cells. Their study, published in Nature, shows that skin generated from p
- Pfizer’s JAK Inhibitor Improves Moderate-to-Severe AD Symptomshttps://practicaldermatology.com/news/pfizers-jak-inhibitor-improves-mild-to-moderate-ad-symptoms/2460413/Results from the second pivotal trial for abrocitinib reinforce the potential symptom relief that this Janus kinase 1 (JAK1) inhibitor offers patients living with moderate to severe atopic dermatitis (AD). Abrocitinib is an investigational oral once-daily JAK1 inhibitor being studied in
- Tremfya Shows Improvement in PsA Joint and Skin Symptomshttps://practicaldermatology.com/news/tremfya-shows-improvement-in-psa-joint-and-skin-symptoms/2460412/Tremfya (guselkumab) demonstrated improvements in multiple clinical outcomes including joint symptoms, skin symptoms, soft tissue inflammation, physical function and reduction in radiographic progression at week 52 in adult patients with active psoriatic arthritis (PsA), according to data fr
- Kymera Therapeutics Initiates Enrollment in Non-Interventional Trial Evaluating IRAK4’s Role in HS and ADhttps://practicaldermatology.com/news/kymera-therapeutics-initiates-enrollment-in-non-interventional-trial-evaluating-irak4s-role-in-hs-and-ad/2460411/Kymera Therapeutics Inc. has started enrollment in a non-interventional trial evaluating IRAK4 expression in patients with hidradenitis suppurativa (HS) and atopic dermatitis (AD). Kymera is developing a selective orally administered IRAK4 degraders for the treatment of toll-like
- Zilxi Approved: First Topical Minocycline Treatment for Rosaceahttps://practicaldermatology.com/news/zilxi-approved-first-topical-minocycline-treatment-for-rosacea/2460408/The FDA has approved Zilxi™ (minocycline) topical foam, 1.5%, from Menlo Therapeutics for the treatment of inflammatory lesions of rosacea in adults. Zilxi, developed as FMX103 by Menlo’s wholly-owned subsidiary Foamix Pharmaceuticals Ltd., is the first minocycline product of any kind
- ASLMS Names New Boardhttps://practicaldermatology.com/news/aslms-names-new-board/2460406/The American Society for Laser Medicine and Surgery (ASLMS) announced its new board during the Board of Directors meeting on April 30, 2020. Thomas E. Rohrer, MD is the new President of ASLMS is the world's largest professional organization dedicated to promoting research, education, and high